Reduction of TTBK1 mRNA decreased levels of phosphorylated TDP-43 in a pathological model, suggesting that TTBK1/2 inhibitors could provide relief for FTD/ALS patients. The gene discussed is TARDBP; the disease is frontotemporal dementia.